Related Experiment Videos

Slow release theophylline in preschool asthmatics

Insights

Slow-release theophylline (Slo-phyllin) offers benefits for wheezing preschool children with asthma. While symptom scores showed no change, active treatment improved other indicators, suggesting its value in managing childhood asthma.

Area of Science:

  • Pediatric Pulmonology
  • Clinical Pharmacology

Background:

  • Asthma is a common chronic respiratory disease in young children.
  • Wheezing in preschool children presents diagnostic and management challenges.
  • Theophylline has been used for asthma, but its efficacy in very young children requires evaluation.

Purpose of the Study:

  • To evaluate the efficacy of slow-release theophylline (Slo-phyllin) in preschool children with asthma.
  • To compare active treatment with placebo using a double-blind crossover design.
  • To assess the utility of symptom scores as a measure of clinical improvement in this age group.

Main Methods:

  • A double-blind, placebo-controlled crossover trial was conducted.
  • Participants were children aged up to 4 years diagnosed with asthma.
  • Patients received either slow-release theophylline or a placebo in a randomized sequence.

Main Results:

  • No significant difference was observed in overall symptom scores between the active treatment and placebo groups.
  • However, other clinical indicators favored the active theophylline treatment.
  • The study highlights potential benefits beyond standard symptom scoring.

Conclusions:

  • Slow-release theophylline (Slo-phyllin) demonstrates benefit in managing wheezing preschool children with asthma.
  • The preparation is a valuable option for this patient population.
  • The study discusses the limitations of symptom scores in assessing clinical improvement in young asthmatic children.

Related Concept Videos